Autoimmunity: Treating type-1 diabetes with an epigenetic drug
- Osaka University, Japan
Type-1 diabetes is an autoimmune disease in which the body's own immune cells attack islet β cells, the cells in the pancreas that produce and release the hormone insulin. Chronic inflammation in the islets (called insulitis) eventually leads to the complete destruction of the β cells, resulting in an insulin deficiency that causes type-1 diabetes. Currently, patients with type-1 diabetes must rely on regular injections of insulin to prevent their blood sugar level from rising too high (a condition called hyperglycaemia). As such, there is great demand for the development of effective treatments that correct the underlying problems that cause type-1 diabetes.
Now in eLife, Diane Mathis, Christophe Benoist and co-workers at the Harvard Medical School and GlaxoSmithKline—including Wenxian Fu as first author—report that a drug called I-BET151 can effectively prevent type-1 diabetes in a mouse model for this disease. The mice spontaneously develop type-1 diabetes when they are still relatively young. Fu et al. show that in addition to preventing insulitis, treating these mice with I-BET151 also reverses pre-existing insulitis, thereby inhibiting the progression of the disease into type-1 diabetes (Fu et al., 2014).
A number of cell types are involved in the development of type-1 diabetes. These cells include: pathogenic T cells that recognise β cells as a target for destruction; antigen-presenting cells that activate the pathogenic T cells; macrophages that release pro-inflammatory molecules such as cytokines; and β cells that respond to these immunological attacks (Eizirik et al., 2009). There are also several potential therapeutics that target some of these disease-causing pathways, for example by neutralizing the cytokines, or by blocking the interaction of T cells and antigen-presenting cells. Other potential treatments that target the causes of type-1 diabetes include promoting the survival and regeneration of β cells, and converting pathogenic T cells into another type of T cell.
In complex diseases like type-1 diabetes, targeting multiple pathways by combining different drugs is thought to offer a more effective way to prevent the disease from progressing while keeping side-effects to a minimum (Matthews et al., 2010). Indeed, the remarkable efficacy of I-BET151 for the treatment of insulitis is attributed to its dual effects on pancreatic macrophages and β cells. While this drug alters the way that macrophages in the pancreas behave in a way that dampens the local inflammation, it also promotes the proliferation of β cells and restores the tissue's function (Figure 1).
Figure 1
The effects of I-BET151 on the resolution of insulitis and the prevention of type-1 diabetes.
Progression to type-1 diabetes is characterised by chronic inflammation and a loss of function of islet β cells (shown in pale orange). This reduces the proliferation of these cells and often leads to a form of programmed cell death called apoptosis (bottom left). Fu et al. reveal that I-BET151 works to resolve inflammation of the islet β cells (insulitis) mainly by two mechanisms. Firstly, it encourages macrophages in the pancreas to convert from being pro-inflammatory (which release cytokines that promote inflammation, top left) to being anti-inflammatory type (top right). This inhibits the further recruitment of T cells and dampens inflammation. Secondly, I-BET151 enhances the proliferation of islet β cells and enhances insulin production (bottom right).
I-BET151 is a synthetic compound, originally generated as a reagent to target the epigenetic codes of the genome (Nicodeme et al., 2010). These codes are chemical modifications on the histone proteins that DNA wraps around, and also on the DNA itself, and they indicate whether expression of a particular gene should be switched on. One type of epigenetic modifications is the acetylation of histones, which is associated with active gene expression. By mimicking the structure of acetylated histones, I-BET151 can interfere with the recognition of acetylated histones by a protein called Brd4, and inhibit the subsequent gene activation. Additionally, other similar Brd4 inhibitors have also been reported to interrupt the binding of Brd4 to an acetylated protein that is a subunit of a transcription factor called NFkB. These inhibitors also repress the expression of inflammation-associated genes, which are normally activated by NFkB (Huang et al., 2009; Zhang et al., 2012; Zou et al., 2014).
To understand the effects of I-BET151 in the course of disease treatment, Fu et al. compared the change in gene expression levels in immune cells caused by administering I-BET151, against the gene expression profiles from over 200 immune cell populations. This comparison elegantly demonstrated that macrophages are the main target of I-BET151. Upon its administration, macrophage reduced the expression of genes that are associated with accelerating inflammation, which was primarily attributed to it inhibiting NFkB-dependent gene activation. Furthermore, I-BET151 increased the expression of molecules with anti-inflammatory properties. In contrast, the effects of I-BET151 on the gene expression of T cells and other immune cells were unexpectedly small. However, chronic inflammation often involves multiple molecules or cells that together act to escalate the inflammatory response. Macrophages and T cells act in this way in the pancreatic tissue of diabetic mice (Yoon et al., 1998; Cantor and Haskins, 2007). Moreover, targeting macrophages using I-BET151 was associated with the reduction in the number of T cells that infiltrate in the tissue, likely contributing to the reversal of insulitis (Fu et al., 2014).
Another critical aspect of the development of type-1 diabetes, along with the inflammation caused by immune cells, is the response of the β cells. Attack by the immune system suppresses the function of the β cells and can cause them to undergo a form of programmed cell death called apoptosis. This, in turn, can further stimulate an immune response (Eizirik et al., 2009). Fu et al. show that I-BET151 enhances the proliferation of β cells in addition to preventing further immunological attacks. This implies that as long as there are functional β cells left, this drug can reverse the disease progression.
With the ability to simultaneously target macrophages and β cells in a cell type-specific manner, I-BET151 appears to be a promising therapeutic drug for the treatment of type-1 diabetes. Whether its effect falls into a category of general immunosuppression, with the possibility of compromising necessary immune responses when applied to humans, will need to be addressed before this drug can be used clinically. It will also be important to determine if there is an appropriate dosage of I-BET151 that treats type-1 diabetes without causing unnecessary epigenetic and transcriptional changes.
References
-
The role of inflammation in insulitis and beta-cell loss in type 1 diabetesNature Reviews Endocrinology 5:219–226.https://doi.org/10.1038/nrendo.2009.21
-
Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelAMolecular and Cellular Biology 29:1375–1387.https://doi.org/10.1128/MCB.01365-08
-
Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment GroupClinical and Experimental Immunology 160:176–184.https://doi.org/10.1111/j.1365-2249.2010.04153.x
-
Down-regulation of NF-kappaB transcriptional activity in HIV-associated kidney disease by BRD4 inhibitionJournal of Biological Chemistry 287:28840–28851.https://doi.org/10.1074/jbc.M112.359505
Article and author information
Author details
Publication history
Copyright
© 2014, Kitagawa and Ohkura
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,522
- views
-
- 200
- downloads
-
- 2
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Autoimmunity: Treating type-1 diabetes with an epigenetic drug
eLife 3:e05720.
https://doi.org/10.7554/eLife.05720
Further reading
-
- Chromosomes and Gene Expression
- Immunology and Inflammation
Genome-wide association studies (GWAS) have identified hundreds of genetic signals associated with autoimmune disease. The majority of these signals are located in non-coding regions and likely impact cis-regulatory elements (cRE). Because cRE function is dynamic across cell types and states, profiling the epigenetic status of cRE across physiological processes is necessary to characterize the molecular mechanisms by which autoimmune variants contribute to disease risk. We localized risk variants from 15 autoimmune GWAS to cRE active during TCR-CD28 co-stimulation of naïve human CD4+ T cells. To characterize how dynamic changes in gene expression correlate with cRE activity, we measured transcript levels, chromatin accessibility, and promoter–cRE contacts across three phases of naive CD4+ T cell activation using RNA-seq, ATAC-seq, and HiC. We identified ~1200 protein-coding genes physically connected to accessible disease-associated variants at 423 GWAS signals, at least one-third of which are dynamically regulated by activation. From these maps, we functionally validated a novel stretch of evolutionarily conserved intergenic enhancers whose activity is required for activation-induced IL2 gene expression in human and mouse, and is influenced by autoimmune-associated genetic variation. The set of genes implicated by this approach are enriched for genes controlling CD4+ T cell function and genes involved in human inborn errors of immunity, and we pharmacologically validated eight implicated genes as novel regulators of T cell activation. These studies directly show how autoimmune variants and the genes they regulate influence processes involved in CD4+ T cell proliferation and activation.
-
- Cell Biology
- Immunology and Inflammation
Arpin was discovered as an inhibitor of the Arp2/3 complex localized at the lamellipodial tip of fibroblasts, where it regulated migration steering. Recently, we showed that arpin stabilizes the epithelial barrier in an Arp2/3-dependent manner. However, the expression and functions of arpin in endothelial cells (EC) have not yet been described. Arpin mRNA and protein are expressed in EC and downregulated by pro-inflammatory cytokines. Arpin depletion in Human Umbilical Vein Endothelial Cells causes the formation of actomyosin stress fibers leading to increased permeability in an Arp2/3-independent manner. Instead, inhibitors of ROCK1 and ZIPK, kinases involved in the generation of stress fibers, normalize the loss-of-arpin effects on actin filaments and permeability. Arpin-deficient mice are viable but show a characteristic vascular phenotype in the lung including edema, microhemorrhage, and vascular congestion, increased F-actin levels, and vascular permeability. Our data show that, apart from being an Arp2/3 inhibitor, arpin is also a regulator of actomyosin contractility and endothelial barrier integrity.
